Efficacy and Safety of MT104, A Dietary Supplement Based on Cuscuta Seeds and Heat-Killed Probiotics, on Cognitive Function in Patients with Mild Cognitive Impairment: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Mild cognitive impairment (MCI) represents the symptomatic predementia stage of Alzheimer's disease (AD).

To delay the progression of MCI to AD, appropriate interventions capable of modulating the microbiota-gut-brain (MGB) axis are necessary.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.

The visuospatial function was assessed using the copying performance from the Rey Complex Figure Test (RCFT), and verbal and visual memory functions were evaluated using the Seoul Verbal Learning Test (SVLT) and RCFT.

What Was Measured

The subject headings attached to it are Cognitive Dysfunction, Probiotics, Dietary Supplements, Cognition, Seeds, Cuscuta and Alzheimer Disease.

The authors tagged it with the keywords MT104, cognitive function, microbiota-gut-brain axis and mild cognitive impairment.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The publication is from 2025 (Journal of medicinal food), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.